Not So Generalized Disorder “Anxiety is a part of normal life.” Or so I was told. Whether I was simply leaving my apartment to get food or speaking during…
Search Results for: MNMD.Q
$901.372M Market Capitalization Mind Medicine Inc. (MNMD.Q) today announced the initiation of a Phase 2a proof-of-concept (POC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit…
Episode 2 Earlier this year Mindmed (MNMD.Q) co-founder JR Rahn went on an epic selling spree, selling nearly 90% of his holdings without telling the public why until days…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
MindMed (MNMD.Q) will participate and assist in the financing of the Digital Medicine Society’s (DiMe) Digital Health Measurement Collaborative Community (DATAcc) in the development of best practices, and the…
MindMed (MNMD.Q) and healthcare data consolidator Datavant, announced a partnership wherein MindMed will make use of Datavant’s tech to link their clinical trial data to external data from both…
MindMed (MNMD.Q) announced they are appointing Dr. Maurizio Fava to their Scientific Advisory Board. Dr. Fava obtained his medical doctorate from the University of Padova School of Medicine, and went…
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…